Experimental drug targets hard-to-treat cancers with unique marker
NCT ID NCT04504942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called leronlimab in 16 adults with advanced solid tumors that have a specific protein (CCR5) on their cells. The main goals were to check safety and see if the drug could slow tumor growth. Participants had already tried other treatments without success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quest Clinical Research
San Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Zinc-Based compound fight cancer?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?
- New imaging agent aims to light up hidden tumors
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
- New scan could reveal hidden cancer cells